ArticleBMC medical genomics2025
Assessment of genetic and metabolite associations of branched chain amino acids with metabolic disease in the UK Biobank using Mendelian randomization.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of BCAAs/BCKAs with pancreatic steatosis in patients with type 2 diabetes mellitus: A cross-sectional study.Journal of diabetes investigation · 2026Article
- Association between Body Fat composition and serum branched chain amino acids in patients with visceral obesity.BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the building blocks of proteins and precursors of many other important compounds, amino acids play a vital role in the biochemical processes needed to sustain life. The branched-chain amino acids (BCAAs) are unique in their structure and function, as they are metabolized in muscle tissue and play important roles in protein synthesis and energy production. However, despite their physiological importance, relatively little integrative research has been conducted into the direct relationships between this class of metabolites and their effect on risk for metabolic diseases.
methodsUtilizing an integrative PheWAS approach using UK Biobank data, we were able to identify strong, high confidence, metabolite-disease correlations for the three BCAAs: leucine, isoleucine, and valine. Relationships were established through comparison of metabolite level-disease prevalence associations with polygenic scores for BCAAs, followed by Mendelian randomization analysis.
resultsAll BCAAs studied demonstrated especially strong relationships with type II diabetes, and robust relationships with obesity, hypertension, sleep apnea, and chronic kidney disease. We illustrate this with a set of metabolite prevalence-disease risk plots that suggest differing potential for disease based on varying levels of branched-chain amino acid metabolites. Similar results are observed with polygenic scores for plasma BCAAs. Mendelian randomization shows positive effects of leucine and isoleucine on hypertension, and either reverse causality or no clear directional relationship for other associations, notably effects of obesity and type II diabetes on all three BCAAs, with limited or borderline evidence for other outcomes.
conclusionsOverall, the results of our study highlight a relatively unexplored area of metabolite-disease associations and provide a blueprint for uncovering additional relationships using readily available biobank data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.